Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

NCT02077634 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.

NCT NCT02077634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02077634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
Lead sponsor
Universität des Saarlandes
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
April 1, 2019
Enrollment
68 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer